SCHEMBL847586

SCHEMBL847586

CC(=O)c1ccc(C)nc1N[C@H]1CC[C@H](O)C1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 12/20 0.45
MAPK9 P45984 5/20 0.41
IRAK4 Q9NWZ3 1/20 0.40
JAK1 P23458 2/20 0.39
JAK3 P52333 2/20 0.39
CHRM3 P20309 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
SYK P43405 1/20 0.36
BTK Q06187 1/20 0.36
FLT3 P36888 1/20 0.36
TYRO3 Q06418 1/20 0.36
MERTK Q12866 1/20 0.36
GAS6 Q14393 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2100940 1.00 MAPK8 (0.45) MAPK8MAPK9IRAK4JAK1JAK3
SCHEMBL848330 1.00 MAPK8 (0.45) MAPK8MAPK9IRAK4JAK1JAK3
SCHEMBL849073 0.92 MAPK8 (0.49) MAPK8MAPK9JAK1JAK3SYK
SCHEMBL847840 0.89 SYK (0.41) IRAK4JAK3CHRM3PDE4APDE4B
SCHEMBL847031 0.83 BTK (0.39) IRAK4JAK3CHRM3PDE4APDE4B
SCHEMBL847497 0.83 SYK (0.45) JAK3CHRM3PDE4APDE4BPDE4C
SCHEMBL848652 0.83 KDM4E (0.43) JAK3CHRM3PDE4APDE4BPDE4C
SCHEMBL847489 0.80 OPRK1 (0.45) IRAK4PDE4BSYKFLT3TYRO3
SCHEMBL846834 0.76 MAPK8 (0.41) MAPK8JAK1SYK
SCHEMBL27800495 0.71 MAPK8 (0.42) MAPK8MAPK9JAK1JAK3CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163906-B2 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO, LLC (US) 2012-04-24 US disclosed
EP-2148862-B1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2012-03-28 EP disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK MAPK9, MAPK10, MAPK1 MAPK8 12/4885MAPK9 1/4885IRAK4 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.